A Phase 3 interventional study of Dapagliflozin and Placebo for Dapagliflozin in Type 2 Diabetes Mellitus and Inadequate Glycaemic Control, sponsored by AstraZeneca. Completed at 110 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2018-10-10.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 19 that started in 2016, is one of 47 in phase 3, and was the 75th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 19 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 905 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 38th largest by enrollment of the 280 interventional ones that give a count, is one of 12 that started in 2016, is one of 119 in phase 3, and was the 258th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
Drug: Dapagliflozin · Drug: Saxagliptin
5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
Drug: Dapagliflozin · Drug: Placebo for Saxagliptin
5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
Drug: Placebo for Dapagliflozin · Drug: Saxagliptin
5mg, orally, Green, plain, diamond-shaped, film-coated tablet
Also known as: Forxiga
Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
Also known as: Onglyza™
Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
Change From Baseline in HbA1c at Week 24
To demonstrate the superiority of the change from baseline HbA1c achieved with the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually after 24 weeks. Results were presented for the modified full analysis set. Note: Baseline was defined as the last assessment on or prior to the date of the first dose of the study medication.
Time frame: Baseline and week 24
Proportion of Participants Achieving HbA1c <7.0% at 24 Weeks
To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually on proportion of participants achieving therapeutic glycaemic response after 24 weeks. Therapeutic glycaemic response was defined as an HbA1c value at Week 24 \<7.0% irrespective of whether participant received rescue medication. Risk difference for each treatment was calculated as adjusted response rate. Participants who did not had an HbA1c measurement at Week 24 were regarded as non-responders. Results were presented for the modified full analysis set.
Time frame: Baseline and week 24
Change in Fasting Plasma Glucose at 24 Weeks
To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5mg to either agent individually on fasting plasma glucose after 24 weeks. Results were presented for the modified full analysis set.
Time frame: Baseline and week 24
Change in Total Body Weight at 24 Weeks
To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to saxagliptin 5 mg on total body weight after 24 weeks. Results were presented for the modified full analysis set.
Time frame: Baseline and week 24
The study was conducted at 119 sites in 6 countries: Canada, Czech Republic, Germany, Mexico, Russia, and United States (US). Approximately 900 participants were to be randomized. Participants with Type 2 Diabetes (T2DM) inadequately controlled on metformin alone were randomized in this study.
| Milestone | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin |
|---|---|---|---|
| Started | 293 | 294 | 296 |
| Participants completed treatment period | 273 | 276 | 283 |
| Completed | 256 | 255 | 243 |
| Not completed | 37 | 39 | 53 |
| Withdrew: Participant decision | 7 | 10 | 9 |
| Withdrew: Adverse event | 10 | 4 | 1 |
| Withdrew: Severe non-compliance to protocol | 2 | 0 | 1 |
| Withdrew: Lack of therapeutic response | 1 | 5 | 14 |
| Withdrew: Study-specific discontinuation criteria | 11 | 13 | 20 |
| Withdrew: Other | 6 | 6 | 7 |
| Withdrew: No treatment given | 0 | 1 | 1 |
| Milestone | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin |
|---|---|---|---|
| Started | 301 | 302 | 302 |
| Participants completed treatment period | 281 | 284 | 289 |
| Completed | 261 | 261 | 248 |
| Not completed | 40 | 41 | 54 |
| Withdrew: Participant decision | 7 | 10 | 9 |
| Withdrew: Adverse event | 10 | 4 | 1 |
| Withdrew: Severe non-compliance to protocol | 2 | 0 | 1 |
| Withdrew: Lack of therapeutic response | 1 | 5 | 14 |
| Withdrew: Study specific discontinuation criteria | 14 | 15 | 21 |
| Withdrew: Other | 6 | 6 | 7 |
| Withdrew: No treatment given | 0 | 1 | 1 |
To demonstrate the superiority of the change from baseline HbA1c achieved with the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually after 24 weeks. Results were presented for the modified full analysis set. Note: Baseline was defined as the last assessment on or prior to the date of the first dose of the study medication.
| Percentage (%) | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin |
|---|---|---|---|
| Change From Baseline in HbA1c at Week 24 | -1.03 ± 0.0558 | -0.63 ± 0.0560 | -0.69 ± 0.0551 |
To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to either agent individually on proportion of participants achieving therapeutic glycaemic response after 24 weeks. Therapeutic glycaemic response was defined as an HbA1c value at Week 24 \<7.0% irrespective of whether participant received rescue medication. Risk difference for each treatment was calculated as adjusted response rate. Participants who did not had an HbA1c measurement at Week 24 were regarded as non-responders. Results were presented for the modified full analysis set.
| Participants | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin |
|---|---|---|---|
| Proportion of Participants Achieving HbA1c <7.0% at 24 Weeks | 124 | 63 | 83 |
To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5mg to either agent individually on fasting plasma glucose after 24 weeks. Results were presented for the modified full analysis set.
| Milligrams per deciliter (mg/dL) | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin |
|---|---|---|---|
| Change in Fasting Plasma Glucose at 24 Weeks | -27.53 ± 2.1557 | -19.95 ± 2.1738 | -12.66 ± 2.1373 |
To demonstrate the effect of the co-administered saxagliptin 5 mg and dapagliflozin 5 mg to saxagliptin 5 mg on total body weight after 24 weeks. Results were presented for the modified full analysis set.
| Kilograms (Kg) | Dapagliflozin + Saxagliptin + Metformin | Saxagliptin + Metformin |
|---|---|---|
| Change in Total Body Weight at 24 Weeks | -2.01 ± 0.1829 | -0.41 ± 0.1815 |
Collected over From time of randomization, and throughout the treatment period and until end of treatment (Visit 5)/early termination + 4 days for non serious AEs and 30 days for SAEs.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin + Saxagliptin + Metformin | 1/293 (0.3%) | 7/293 (2.4%) | 41/293 (14%) |
| Dapagliflozin + Metformin | 2/293 (0.7%) | 8/293 (2.7%) | 39/293 (13.3%) |
| Saxagliptin + Metformin | 0/295 (0%) | 7/295 (2.4%) | 29/295 (9.8%) |
| Event | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin |
|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/293 | 2/293 | 0/295 |
| Angina unstableCardiac disorders | 1/293 | 0/293 | 0/295 |
| Coronary artery diseaseCardiac disorders | 1/293 | 0/293 | 0/295 |
| Myocardial infarctionCardiac disorders | 0/293 | 1/293 | 0/295 |
| TachycardiaCardiac disorders | 0/293 | 1/293 | 0/295 |
| Ventricular arrhythmiaCardiac disorders | 0/293 | 1/293 | 0/295 |
| Radius fractureInjury, poisoning and procedural complications | 1/293 | 0/293 | 0/295 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/293 | 0/293 | 0/295 |
| Sternal fractureInjury, poisoning and procedural complications | 1/293 | 0/293 | 0/295 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/293 | 1/293 | 0/295 |
| Event | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin |
|---|---|---|---|
| Glomerular filtration rate decreasedInvestigations | 12/293 | 11/293 | 5/295 |
| Viral upper respiratory tract infectionInfections and infestations | 5/293 | 9/293 | 8/295 |
| InfluenzaInfections and infestations | 3/293 | 9/293 | 3/295 |
| Urinary tract infectionInfections and infestations | 7/293 | 3/293 | 5/295 |
| PollakiuriaRenal and urinary disorders | 7/293 | 1/293 | 0/295 |
| NauseaGastrointestinal disorders | 6/293 | 5/293 | 3/295 |
| Upper respiratory tract infectionInfections and infestations | 3/293 | 4/293 | 6/295 |
Full analysis set (FAS): All randomized participants who took at least 1 dose of study drug \& had baseline value for HbA1c. Analysis was based on randomized treatment. Modified FAS - all participants from FAS with the exception of participants from one site (United States; excluded due to serious Good Clinical Practice \[GCP\] violations).
| Age, Continuous(Years) | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin | Total |
|---|---|---|---|---|
| Mean | 57.2 ± 10.68 | 55.9 ± 10.94 | 57.0 ± 9.94 | 56.7 ± 10.53 |
| Sex: Female, Male(Participants) | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin | Total |
|---|---|---|---|---|
| Female | 148 | 137 | 134 | 419 |
| Male | 142 | 152 | 157 | 451 |
| Ethnicity (NIH/OMB)(Participants) | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin | Total |
|---|---|---|---|---|
| Hispanic or Latino | 99 | 95 | 99 | 293 |
| Not Hispanic or Latino | 191 | 194 | 192 | 577 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dapagliflozin + Saxagliptin + Metformin | Dapagliflozin + Metformin | Saxagliptin + Metformin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 0 | 4 |
| Asian | 9 | 9 | 6 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 17 | 24 | 51 |
| White | 265 | 257 | 258 | 780 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 3 | 3 | 11 |
Showing the first 100 of 110 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2016 to primary completion in Jul 2017, 16 months.
Results were first posted in Oct 2018, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dapagliflozin · Saxagliptin